| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Escitalopram[1] | SSRI | 10 mg PO daily start, titrate to 10–20 mg/day | — | First-line; QTc warning at higher doses; relatively few drug interactions; review at 2–4 weeks, full effect 4–6 weeks |
| Sertraline[1] | SSRI | 50 mg PO daily start, titrate to 100–200 mg/day | — | First-line; activating, weight-neutral; counsel about initial activation and suicide warning <25 years |
| Mirtazapine[1] | Tetracyclic antidepressant | 15 mg PO night start, titrate to 30–45 mg night | — | Useful with insomnia, weight loss, comorbid anxiety; sedating at lower doses; weight gain; less sexual dysfunction than SSRIs |
| Venlafaxine extended-release[1] | SNRI | 75 mg PO daily start, titrate to 150–225 mg/day | — | Second-line if SSRI inadequate; monitor BP at higher doses; discontinuation syndrome — taper |
| Amitriptyline (TCA)[1] | Tricyclic antidepressant | Start 25 mg PO night, titrate to 75–150 mg | — | Effective but anticholinergic, cardiotoxic in overdose; reserve for refractory or comorbid neuropathic pain/insomnia; ECG before higher dose |
| Lithium (augmentation)[1] | Mood stabiliser | Start 400 mg PO daily, titrate to plasma 0.4–0.8 mmol/L | — | Augmentation in treatment-resistant depression; renal and thyroid function monitoring; teratogen |
| Olanzapine + fluoxetine combination (TRD or psychotic depression)[1] | Atypical antipsychotic + SSRI | Olanzapine 5–10 mg PO + fluoxetine 20–40 mg PO daily | — | Treatment-resistant or psychotic depression; metabolic monitoring |
Diagnosis and stepwise pharmacological + psychological management of depressive disorder in adults.